Compound News and Research

RSS

Laboratory for Molecular Biodiscovery, KU Leuven partner for €9.5M 'PharmaSea' project

KU Leuven scientist Camila Esguerra and the Laboratory for Molecular Biodiscovery are coordinating a €9.5 million, EU-funded project to collect and study marine microbes extracted from some of the ocean's deepest, most extreme - and as-yet-unexplored -biomes.

12 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

12 Mar 2013

Combining mitochondrial inhibitors could improve efficacy of BRAF inhibitors in melanoma

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism.

11 Mar 2013

Novel drug seems to increase effectiveness of usual chemotherapy against IBC

Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form of breast cancer.

8 Mar 2013

Targeting ARF6 may be effectively prevent melanoma metastasis to lungs

Researchers have identified a critical protein role in the metastasis of melanoma, the most serious form of skin cancer.

6 Mar 2013

Five green powerhouse foods to help stylize your plate

The energetic and radiant hue of emerald green has been declared the spring color of 2013. While green shirts, pants and jackets will be seen everywhere this season, so should green food on your plate.

6 Mar 2013

tRNA synthetases play unexpected and critical role in cancer metastasis

Studied for decades for their essential role in making proteins within cells, several amino acids known as tRNA synthetases were recently found to have an unexpected - and critical - additional role in cancer metastasis in a study conducted collaboratively in the labs of Karen Lounsbury, Ph.D., University of Vermont professor of pharmacology, and Christopher Francklyn, Ph.D., UVM professor of biochemistry.

5 Mar 2013

Microcystins in drinking water

An interview with Rohan Thakur, discussing the prevalence of microcystins in drinking water, and the use of LC-MS to identify cyanotoxins within water samples.

From Bruker Daltonics 5 Mar 2013

Sanford-Burnham enters into partnership to test furin for treatment of dengue fever

Sanford-Burnham Medical Research Institute and 60- Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics.

5 Mar 2013

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.

4 Mar 2013

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

UNC1215 chemical probe can help investigate L3MBTL3 methyl-lysine reader domain

In an article published as the cover story of the March 2013 issue of Nature Chemical Biology, Lindsey James, PhD, research assistant professor in the lab of Stephen Frye, Fred Eshelman Distinguished Professor in the UNC School of Pharmacy and member of the UNC Lineberger Comprehensive Cancer Center, announced the discovery of a chemical probe that can be used to investigate the L3MBTL3 methyl-lysine reader domain.

3 Mar 2013

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).

1 Mar 2013

Medical Adhesives for Reusable or Disposable Medical Devices

An interview with Robert Michaels, discussing the major challenges faced by engineers designing medical devices and the development of new medical adhesives.

From Master Bond Inc. 28 Feb 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Study designs and tests 60 compounds for their ability to kill human cancer cells

Inspired by a chemical that fungi secrete to defend their territory, MIT chemists have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.

28 Feb 2013

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

27 Feb 2013

Surgical site infections appear to have significant genetic connections

An estimated 300,000 U.S. patients get surgical site infections every year, and while the causes are varied, a new University of Utah study suggests that some who get an infection can blame it partly on their genes.

27 Feb 2013

4SC Discovery enters exclusive research and license agreement with LEO Pharma

LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.

26 Feb 2013

Compound News and Research

Laboratory for Molecular Biodiscovery, KU Leuven partner for €9.5M 'PharmaSea' project

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Combining mitochondrial inhibitors could improve efficacy of BRAF inhibitors in melanoma

Novel drug seems to increase effectiveness of usual chemotherapy against IBC

Targeting ARF6 may be effectively prevent melanoma metastasis to lungs

Five green powerhouse foods to help stylize your plate

tRNA synthetases play unexpected and critical role in cancer metastasis

Microcystins in drinking water

Sanford-Burnham enters into partnership to test furin for treatment of dengue fever

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

UNC1215 chemical probe can help investigate L3MBTL3 methyl-lysine reader domain

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Medical Adhesives for Reusable or Disposable Medical Devices

EpiCept fourth quarter revenue decreases to $0.1 million

Study designs and tests 60 compounds for their ability to kill human cancer cells

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Surgical site infections appear to have significant genetic connections

4SC Discovery enters exclusive research and license agreement with LEO Pharma

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News